A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial XXXX .

@entity1 @entity137 @entity295 @entity39 @entity5 @entity3003 @entity786 @entity2879 @entity421 @entity204
BACKGROUND: This pilot study was undertaken to assess the feasibility, @entity137 and response to short-course multiagent chemotherapy followed by high-dose chemotherapy (HDC) in @entity1 with poor prognosis @entity421 . @entity1 AND METHODS: A total of 30 @entity1 entered the study. Chemotherapy consisted of four blocks of multiagent chemotherapy administered sequentially over a short period in a dose-intensive manner. This therapy was followed by HDC which consisted of @entity3003 at an AUC8 x 3 days, @entity2879 400 mg/m(2) x 3 days and @entity786 60 mg/kg x 2 days. RESULTS: A total of 227 cycles of chemotherapy were administered. The main @entity137 (for blocks 1-4) was haematological. There were two treatment-related @entity204 : one post HDC due to @entity295 and one during surgery. High-dose chemotherapy was administered to 11 @entity1 (10 with @entity5 and only one with a @entity5 ). Twenty-seven @entity1 underwent surgery to the primary. Histological response was assessed in 23 @entity1 . Seven @entity1 (30%) had >90% @entity39 . Eight @entity1 underwent pulmonary metastatectomy. The median survival time for the whole group was 16 months. The 2- and 3-year survival rates were 50% and 21% for those with @entity5 and 19% and 13% for those with @entity5 . CONCLUSIONS: Dose-intensive multiagent chemotherapy though feasible in the group of @entity1 with @entity5 did not significantly improve the treatment outcome compared with conventional relapse therapy. Inferior survival rates in the axial skeletal group are attributed to less intensive treatment and poor @entity5 control.
